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Significance
The emergence of multidrug-resistant bacteria, including uropathogenic Escherichia coli (UPEC), makes the development of
targeted antivirulence therapeutics a critical focus of research.
During urinary tract infections (UTIs), UPEC uses chaperone–
usher pathway pili tipped with an array of adhesins that recognize distinct receptors with sterochemical specificity to facilitate
persistence in various tissues and habitats. We used an interdisciplinary approach driven by structural biology and synthetic glycoside chemistry to design and optimize glycomimetic
inhibitors of the UPEC adhesin FmlH. These inhibitors competitively blocked FmlH in vitro, in in vivo mouse UTI models, and
in ex vivo healthy human kidney tissue. This work demonstrates the utility of structure-driven drug design in the effort
to develop antivirulence therapeutic compounds.

|

rinary tract infections (UTIs) are one of the most prevalent
infections, afflicting 15 million women per year in the United
States alone, with annual healthcare costs exceeding $2 to $3 billion
(1–3). Nearly 50% of women will experience at least one UTI in
their lifetime. Despite appropriate and often successful clearance of
bacteriuria by antibiotic treatment, 20% to 30% of women will
experience a recurrence within 6 mo of the initial acute UTI (1, 4).
Kidney infection, or pyelonephritis, represents a severe manifestation of UTI, with ∼250,000 cases and 100,000 hospitalizations
per year in the United States (5). Acute pyelonephritis requires
hospital admission and i.v. antibiotics to thwart the long-term
sequelae of kidney failure and renal scarring, and, together with
bacteremia, results in a mortality rate of 10% to 20% (6–8). With
the global dissemination and increase of antibiotic resistance,
treatment of UTI is becoming a serious clinical challenge (9). Antibiotic susceptibility tests indicate that many uropathogens are resistant
to traditional first-line antibiotics like trimethoprim-sulfamethoxazole
(TMP-SMZ) and even to last-line antibiotics such as ciprofloxacin
and colistin (10–15). The diminishing efficacy of antibiotic therapies toward UTIs and other infectious diseases demands alternawww.pnas.org/cgi/doi/10.1073/pnas.1720140115

tive antibiotic-sparing approaches to combat bacterial pathogens.
Recently, promising efforts have been made to target the virulence
mechanisms that cause bacterial infection. These studies have
provided much-needed therapeutic alternatives, which simultaneously reduce the burden of antibiotic resistance and minimize
disruption of gastrointestinal microbial communities that are
beneficial to human health (16).
Uropathogenic Escherichia coli (UPEC) is the main etiological
agent of UTIs, accounting for greater than 80% of communityacquired UTIs (17, 18). Comparative genomic studies have revealed
that UPEC strains are remarkably diverse, such that only 60% of the
genome is shared among all strains (19). As a consequence, UTI risk
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Treatment of bacterial infections is becoming a serious clinical
challenge due to the global dissemination of multidrug antibiotic
resistance, necessitating the search for alternative treatments to
disarm the virulence mechanisms underlying these infections.
Uropathogenic Escherichia coli (UPEC) employs multiple chaperone–
usher pathway pili tipped with adhesins with diverse receptor specificities to colonize various host tissues and habitats. For example,
UPEC F9 pili specifically bind galactose or N-acetylgalactosamine
epitopes on the kidney and inflamed bladder. Using X-ray structureguided methods, virtual screening, and multiplex ELISA arrays, we
rationally designed aryl galactosides and N-acetylgalactosaminosides
that inhibit the F9 pilus adhesin FmlH. The lead compound, 29β-NAc,
is a biphenyl N-acetyl-β-galactosaminoside with a Ki of ∼90 nM,
representing a major advancement in potency relative to the characteristically weak nature of most carbohydrate–lectin interactions.
29β-NAc binds tightly to FmlH by engaging the residues Y46 through
edge-to-face π-stacking with its A-phenyl ring, R142 in a salt-bridge
interaction with its carboxylate group, and K132 through watermediated hydrogen bonding with its N-acetyl group. Administration
of 29β-NAc in a mouse urinary tract infection (UTI) model significantly reduced bladder and kidney bacterial burdens, and coadministration of 29β-NAc and mannoside 4Z269, which targets the type
1 pilus adhesin FimH, resulted in greater elimination of bacteria from
the urinary tract than either compound alone. Moreover, FmlH specifically binds healthy human kidney tissue in a 29β-NAc–inhibitable
manner, suggesting a key role for F9 pili in human kidney colonization. Thus, these glycoside antagonists of FmlH represent a rational
antivirulence strategy for UPEC-mediated UTI treatment.

and outcome are determined by complex interactions between host
susceptibility and diverse bacterial urovirulence potentials, which
can be driven by differences in the expression and regulation of
conserved functions. The ability of UPEC to colonize various
habitats, such as the gut, kidney, and bladder, depends in large
part on the repertoire of adhesins encoded in their genome. The
most common mechanism for adhesion utilized by UPEC is mediated through the chaperone–usher pathway (CUP), which generates
extracellular fibers termed pili that can confer bacterial adhesion
to host and environmental surfaces, facilitate invasion into host
tissues, and promote interaction with other bacteria to form biofilms
(20). Phylogenetic analysis of Escherichia genomes and plasmids
predicts at least 38 distinct CUP pilus types, with single organisms
capable of maintaining as many as 16 distinct CUP operons (21).
Many of these CUP pilus operons contain two-domain, tip-localized
adhesins, each of which likely recognize specific ligands or receptors
to mediate colonization of a host and/or environmental niche.
For example, the type 1 pilus adhesin FimH binds mannosylated
glycoproteins on the surface of the bladder epithelium, which is
crucial for the establishment of cystitis (22, 23). The structural
basis of mannose (Man) recognition by the N-terminal–receptor
binding domain, or lectin domain (LD), of FimH has been leveraged to rationally develop high-affinity aryl mannosides (24–32). In
mouse models of UTI, we have previously demonstrated that orally
bioavailable mannosides that tightly bind FimH can prevent acute
UTI, treat chronic UTI, and potentiate the efficacy of existing antibiotic treatments like TMP-SMZ, even against antibiotic-resistant
E. coli strains (28). Thus, use of mannosides that target the adhesin
FimH represents the first successful application of an antivirulence
strategy in the treatment of UTI.
A homolog of the type 1 pilus, the F9 pilus, is one of the most
common CUP pili in the E. coli pan genome and an important
urovirulence factor employed by UPEC for the maintenance of
UTI (21, 33). Our recent work has demonstrated that UPEC upregulates the expression of F9 pili in response to bladder inflammation and epithelial remodeling induced upon UPEC infection
(34). These pili display the FimH-like adhesin FmlH, which is
capable of binding terminal galactose (Gal), N-acetylgalactosamine
(GalNAc), or Thomsen-Friedenreich antigen (TF) [Gal(β1-3)GalNAc(α)]. FmlH was shown to bind TF within naïve or infected kidneys and to Thomsen nouvelle antigen (Tn) (GalNAc) within the
inflamed bladder epithelium during chronic, unresolved UTI. Deletion of FmlH in the urosepsis isolate CFT073 resulted in a
competitive defect in the ability of this strain to maintain murine
UTI in C3H/HeN female mice. Furthermore, vaccination with the
LD of FmlH (FmlHLD) as the challenge antigen significantly
protected mice from developing UTI. Thus, we have shown that
FmlH serves a key role in the UPEC pathogenesis cascade and
represents a promising target for antivirulence therapies for UTI
in both the bladder and kidney habitats.
Herein, we describe the discovery and structure-based optimization of high-affinity aryl galactoside and N-acetylgalactosaminoside
FmlH ligands that potently inhibit the function of FmlH. Treatment
with these FmlH antagonists significantly reduced bacterial burdens
in the kidneys and bladders of infected mice, thereby demonstrating
promising translational value in the treatment of UTI in humans.
The results of these studies, together with our previous work on FimH
mannosides, further support the mechanistic and therapeutic value of
antivirulence strategies that leverage structure-function relationships
of diverse bacterial adhesins for the rational design of high-affinity
glycosides for the treatment of UTI and other bacterial infections.
Results
O-nitrophenyl β-Galactoside Identified as Early Lead Inhibitor of the
F9 Pilus Adhesin FmlH. We revealed in a previous communication

that FmlH binds surface glycan receptors containing terminal
Gal, GalNAc, or TF residues (34). Given the role of FmlH in UTI
pathogenesis, we aimed to develop high-affinity galactoside
E2820 | www.pnas.org/cgi/doi/10.1073/pnas.1720140115

antagonists of FmlH through an X-ray structure-guided medicinal chemistry approach. This strategy entailed (i) screening
a select library of galactosides through multiplex ELISA arrays
for initial lead compund identification; (ii) an iterative process of
cocrystal structure determination, virtual screening, structurebased ligand design, and in vitro biochemical characterization;
and (iii) evaluation of the top lead compound in a mouse model of
UTI (Fig. 1A). Toward these goals, we first investigated whether
Gal, GalNAc, and TF could be adapted to function as soluble,
competitive inhibitors of FmlH. To that end, an ELISA-based
competition assay was developed to detect binding of FmlHLD to
surface-immobilized desialylated bovine submaxillary mucin (dsBSM) in the presence or absence of soluble compounds (Fig. 1A).
As expected, Gal, GalNAc, and TF were each capable of inhibiting
FmlHLD at a concentration of 1 mM, with GalNAc exerting greater
inhibitory potency than TF or Gal. However, neither Man nor
glucose (Glc) had any detectable effect on the ability of FmlHLD
to bind ds-BSM (Fig. 1B). Lactose (Lac), or Gal(β1-4)Glc, was
also incapable of inhibiting FmlHLD, demonstrating the high selectivity in which FmlHLD engages Gal-containing glycans (Fig. 1B). Onitrophenyl β-galactoside (ONPG) and isopropyl β-thiogalactoside
(IPTG) were also tested for inhibition in this exploratory phase
of our search for FmlH inhibitors. While IPTG exerted minor inhibitory activity at 100 μM, ONPG was found to block FmlHLD from
interacting with ds-BSM more effectively than Gal, GalNAc, or
TF (Fig. 1B). The strong inhibitory potency of ONPG suggested
that β-galactosides could potentially be rationally designed with
higher affinity by specifically targeting residues within and surrounding the sugar binding pocket of FmlH.
Therefore, X-ray crystallography was implemented to elucidate the 3D structures of both apo and ligand-bound FmlHLD
(SI Appendix, Table S1). First, a crystal structure of apo FmlHLD
was solved at 1.6 Å resolution by molecular replacement using
FimHLD [Protein Data Bank (PDB) ID 3MCY] as the search model.
Within this structure, two copies of FmlHLD are found in the asymmetric unit, each of which adopts a canonical β-sandwich fold,
with three distinct binding loops (loop 1: residues 10 to 15; loop
2: residues 44 to 53; and loop 3: residues 132 to 142) that form a
wide, shallow, solvent-exposed binding pocket (Fig. 1 C and D).
Within the binding pocket of both copies resides a sulfate ion,
which interacts with residues implicated in Gal binding (Fig. 1D).
Cocrystal structures of FmlHLD bound to TF and of FmlHLD bound
to ONPG were also solved to 2.1 Å and 1.8 Å, respectively. Structural overlay of the apo and ligated crystal structures yields rootmean-square deviation (RMSD) values that fall within 0.6 Å,
suggesting that FmlHLD generally adopts the same active or functional conformational state in the absence or presence of ligand
(Fig. 1C). This functional conformational state most likely corresponds to a high-affinity conformation of FmlH, as the FmlHLD
structures exhibit a higher degree of structural homology to the
high-affinity conformation of FimH (RMSD values of 0.8 to 0.9 Å)
than to the low-affinity conformation of FimH (RMSD values of
1.7 to 1.9 Å) (34–38).
The cocrystal structure of FmlHLD-TF reveals two copies of
FmlHLD-TF in the unit cell, in which each TF adopts a distinct
ligand conformation (Fig. 1D). In both copies, the terminal Gal
in TF occupies the cleft of the binding pocket through direct
polar interactions with residues F1, D53, K132, and N140. In
contrast, the orientation of the GalNAc in TF differs significantly between the two copies of FmlH. In chain A, the GalNAc
sugar points toward loop 3, with the carbonyl group of GalNAc
forming a hydrogen bond (H-bond) with the guanidinium group
of R142. In chain B, however, the GalNAc packs against and
forms a H-bond with the hydroxyl group of Y46. Accordingly, the
differences in the orientation of bound ligand across the two
copies are accompanied by slight differences in orientation of the
side chains of the interacting residues Y46 and R142. The multiple binding modes observed for a single ligand suggests that the
Kalas et al.

wide, shallow nature of the Gal binding pocket in FmlH would
enable galactosides to possibly bind FmlH with diverse interactions and conformations.
The FmlHLD-ONPG cocrystal structure also shows two copies
of FmlHLD in the unit cell, in which a sulfate ion occupies the
binding pocket of chain A while ONPG occupies the binding
pocket of chain B (Fig. 1D). As expected, the Gal component of
ONPG resides in the cleft of the binding pocket, while the solventexposed nitrophenyl group mediates a polar or salt-bridge interaction with R142 through an intricate network of H-bonds with
water molecules. Furthermore, the positioning of the Gal component of ONPG aligns with that of the Gal residue of TF (Fig. 1C).
Moreover, the conformation of the FmlH binding pocket observed
in this FmlHLD-ONPG cocrystal structure resembles the binding
pocket conformation in the FmlHLD-TF cocrystal structure, reflecting a high-affinity binding orientation that can be targeted for
drug discovery. These results and observations strongly suggested
that the FmlHLD-ONPG cocrystal structure represents an appropriate structural candidate for use in virtual screening to aid in the
design of galactoside compounds specific for FmlH.
Kalas et al.

Virtual Screen Identifies and Informs the Design of FmlH-Targeting
Galactosides. An exhaustive virtual screen was performed using

AutoDock Vina to computationally dock ∼1,800 known galactosides in the binding pocket of FmlHLD (from an FmlHLDONPG cocrystal structure; PDB ID 6AOY), generating a ranked
list of top binding poses and associated docking scores for each
galactoside (SI Appendix, Fig. S1A). Top hits from the virtual
screen were filtered according to group efficiency values and then
visually inspected to aid and inform structure-guided drug design.
In all cases, the Gal component of top-scoring galactosides bound
to the cleft of the binding pocket, as expected. In addition, most of
the high-scoring hits also interacted with specific hot-spot residues
near the Gal binding pocket, which we sought to leverage for compound optimization. These hot-spot residues included (i) residue
Y46, which caps the top of the binding pocket and can contribute
hydrophobic interactions; (ii) residue K132, which lies at the bottom
of the sugar binding pocket and can engage polar groups linked to
the Gal sugar; and (iii) residue R142, which points toward an empty,
solvent-exposed cleft near the binding pocket and can contribute
electrostatic interactions (SI Appendix, Fig. S1B). These visual
PNAS | vol. 115 | no. 12 | E2821
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Fig. 1. Biochemical and structural characterization of early galactoside antagonists of FmlH. (A) Strategy for structure-guided drug design and evaluation of
FmlH-targeting galactosides. A select library of galactosides were initially assessed in an ELISA-based competition assay for inhibition of FmlH binding to
sialidase-treated BSM, with BSM indicated by gray circles, TF residues indicated by the yellow square-circle conjugates, biotinylated FmlHLD by blue rectangles,
and galactosides shown as colored circles. Cocrystal structures of FmlHLD bound to a lead compound facilitated virtual screening and structure-guided drug
design for biochemical evaluation of an expanded galactoside library. The top lead compound would then be tested as a treatment in a mouse model of UTI.
(B) ELISA-based competition assay performed in triplicate in the absence or presence of 1 mM or 0.1 mM compounds with at least two biological replicates.
Data are reported as the mean percent inhibition, with the box indicating the 25th to 75th percentiles and the whiskers indicating the 2.5th and 97.5th
percentiles. (C) Structural alignment of FmlHLD from an apo FmlHLD crystal structure (PDB ID 6AOW), a FmlHLD-TF cocrystal structure (PDB ID 6AOX), and a
FmlHLD-ONPG cocrystal structure (PDB ID 6AOY). (D) Crystal structures of sulfate ions or ligands bound in the FmlHLD binding pocket, with H-bonding (black
dashed lines) indicated between sulfate ions (yellow sticks), ligands (green sticks), water molecules (red spheres), or side chains (pink sticks).

insights were then considered in our rational design strategy for
FmlH-targeting galactoside antagonists.
Design and Synthesis of FmlH-Targeting Galactoside Antagonists. To
increase FmlH binding affinity and explore structure-activity
relationships (SARs), we constructed a large library of galactoside analogs (Fig. 2). Based on the docking results, we predicted
that β-Gal isomers would be preferred over α-Gal and that ortho
positioning of functional groups on a phenyl scaffold would best
facilitate interactions with specific sites within the binding pocket,
namely hot-spot residues Y46 and R142. Accordingly, we synthesized and evaluated small sets of phenyl galactosides with orthosubstituted functional groups (2 to 6; Fig. 2A). We also either
purchased or synthesized several other phenyl galactosides, which
contained meta or para substituents on the aglycone ring (7 to 11;
Fig. 2A), and other aryl and heterocyclic galactosides (12 to 22;
Fig. 2 B and C). This allowed us to derive meaningful SARs for
informing further design and optimization of improved galactosides. In addition, we tested natural-product galactosides isolated from cranberries and other natural sources (23 to 27; Fig.
2D). The promising activity of the simple galactoside ONPG (4β)
in the initial screen, coupled with the hot-spot residues identified
in virtual screening, prompted us to expand our FmlH-ligand design
strategy with a compound series containing biphenyl aglycones (28
to 32; Fig. 2E), such as 29β-NAc, the N-acetyl-β-galactosaminoside
with an m-carboxylic acid on the B-ring designed to directly interact with the hot-spot residue R142 (SI Appendix, Fig. S1 B and
C). To confirm the predicted preference for the β-Gal isomers, we
also synthesized and tested many corresponding α-Gal isomers.
Compounds were synthesized by using one of two general synthetic
glycosylation methods involving either a reaction between Gal
pentaacetate and phenols promoted by boron trifluoride or a
Koenigs–Knorr-type reaction of galactosyl halide with aryl alcohols
(SI Appendix, Fig. S2).
Biochemical Characterization of FmlH Antagonists. Selected top-hit
glycosides and a few low-scoring analogs from the virtual screen,
as well as synthetic galactosides, were tested in the ELISA-based
competition assay for their ability to inhibit binding of FmlHLD
to ds-BSM. Direct comparison of inhibitory potency among
galactosides led to delineation of basic SARs (Fig. 3 A–C and
SI Appendix, Table S2). When tested at 100 μM, the phenyl
β-galactoside 1β (beta isomer of 1; Fig. 2A) exhibited significantly
higher binding inhibition (77%) than Gal (8.1%), indicating that the
phenyl group significantly enhances binding to FmlHLD (Fig. 3A).
Various ortho substituents on the phenyl ring additionally conferred
substantial improvements in inhibitory potency, as observed with 2β
(87%), 3β (95%), 4β (ONPG; 93%), 5β (97%), and 6β (90%). In
contrast, the meta-methoxy groups in compound 7β (76%) did not
enhance binding strength compared with 1β. Further, parasubstituted functional groups displayed variable inhibitory potencies relative to 1β, with enhancements observed in 8β (86%) and
9β (86%), with no significant effect observed in 11β (78%) or
11β-thio (72%), and with a reduction observed in 10β (65%).
Thus, we deduced that the ortho-substituted phenyl β-galactosides
generally outperformed other simple phenyl galactosides.
Complex heterocyclic galactosides, such as coumarins 12β (85%)
and 14β (89%), which differ only by a methyl group, displayed
significant inhibitory potencies against FmlHLD, while the related
galactoside 13β (50%) displayed reduced inhibitory activity, likely
because of its fluoro substituents (Fig. 3A and SI Appendix, Table
S2). Resorufin galactoside 15β (80%) also showed similar potency
compared with the phenyl β-galactoside 1β. These combined results
suggest that the substituents of 12β are responsible for augmenting
affinity relative to 1β. In contrast, indoles 16β (22%) and 17β
(41%) performed poorly as inhibitors of FmlHLD. Naphthyl galactosides 18β (46%) and 19β (79%), in addition to isoquinoline 21β
(15%), showed no improvement in activity relative to 1β. However,
E2822 | www.pnas.org/cgi/doi/10.1073/pnas.1720140115

Fig. 2. Grouped organization of galactosides evaluated for FmlHLD inhibition. The major groups include the phenyl (A), heterocyclic (B), napthyl/
quinoline/phenylethyl (C), natural product (D), and biphenyl (E) series.

quinoline 20β (95%) displayed significantly higher inhibition
than 1β and 18β. This advocates that the electron pair-donating
nitrogen atom in 20β is making a specific interaction with FmlH.
This observation is consistent with the pattern of SARs, indicating that the ortho position is key to enhancing inhibitory
potency against FmlHLD.
Kalas et al.

We also evaluated naturally occurring galactosides derived
from cranberries and other natural sources in this screen (Fig. 3A
and SI Appendix, Table S2). These compounds included anthocyanidin (pelargonidin, 23β; cyanidin, 24β; peonidin, 25β) and
flavonol (quercetin, 26β; myricetin, 27β) β-galactosides. Generally, these compounds exhibited moderate to weak inhibition of
FmlHLD binding, with little enhancement in inhibition relative to
Gal (8.1%). The only significant binders were 24β (29%) and
Kalas et al.

26β (14%). Comparison of the anthocyanidin family indicates
that the 3′ or meta-substituted hydroxyl group on the B-ring of
24β is critical for its specific interaction with FmlH. Absence of
this meta substituent in 23β (0.7%) or methylation of the hydroxyl group in 25β (3.6%) abrogates potency, suggesting that
the hydroxyl group of 24β might participate in a H-bond to a
specific residue in the FmlHLD binding pocket. Additional inhibitory screens performed with cranberry-derived compounds
PNAS | vol. 115 | no. 12 | E2823
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Fig. 3. In vitro screening and affinity determination of galactosides against FmlHLD. (A–C) ELISA-based competition assay performed in triplicate in the
absence or presence of (A) 100 μM, (B) 10 μM, and (C) 1 μM compounds with at least two biological replicates. Data are reported as the mean percent inhibition, with the box indicating the 25th to 75th percentiles and the whiskers indicating the 2.5th and 97.5th percentiles. a, α; b, β. (D, Left) Schematic of
conventional BLI experiment, in which pins coated with streptavidin (orange stars) are loaded with biotinylated Ser-TF (gray ovals and yellow square-circle
conjugates) and dipped into solutions of varying concentrations of FmlHLD (blue rectangles). (Right) Equilibrium analysis of soluble FmlHLD binding to
immobilized Ser-TF according to a 1:1 binding model. (E, Left) Schematic of competitive BLI experiment, in which streptavidin-coated pins are dipped into a
solution composed of a fixed concentration of FmlHLD in the presence of varying concentrations of galactoside (yellow circles). (Right) Equilibrium constants
of soluble galactoside-mediated inhibition of FmlHLD in binding immobilized Ser-TF in accord with R2 > 0.85.

Fig. 4. Structural basis of galactoside inhibition of FmlHLD. (A) Crystal structures of sulfate ions or galactosides bound in the FmlHLD binding pocket, with
H-bonding (black dashed lines) indicated between sulfate ions (yellow sticks), ligands (green sticks), water molecules (red spheres), or side chains (pink sticks).
Crystal structures shown here include an apo FmlHLD crystal structure (PDB ID 6AOW), a FmlHLD-4β cocrystal structure (PDB ID 6ARM), a FmlHLD-5β cocrystal
structure (PDB ID 6ARN), and a FmlHLD-20β cocrystal structure (PDB ID 6ARO). (B) Cocrystal structure of 29β-NAc bound to FmlHLD (PDB ID 6AS8). (C) SARs for
29β-NAc and related compounds, with their corresponding IC50 values derived from the ELISA-based competition assay. IC50 values are reported for six
replicates as the mean with SEM.

and fractions at 1 mM confirmed the specificity and necessity of
the Gal sugar for inhibiting the binding pocket of FmlH (SI
Appendix, Fig. S3 A and B).
Interestingly, the tested GalNAc-derived compounds possessed significantly higher inhibitory potency compared with
their matched-pair Gal-derived counterparts, as exemplified with
4β-NAc (87%) relative to 4β (31%) when tested for inhibition at
10 μM (Fig. 3B and SI Appendix, Table S2). These results taught
us that the N-acetyl group, together with other functional groups,
contributes to binding by targeting distinct components of the
binding pocket of FmlH. In contrast, the galactosides with
α-linkages (28α-30α) or disaccharides with aglycone moieties (33
to 35) were generally poor inhibitors of FmlH, except for 11αNAc (82%) (Fig. 3A and SI Appendix, Table S2).
Consistent with the above-mentioned SARs, the ortho biphenyl
galactoside 28β (91%) was more potent than the meta 31β (57%)
or para 32β (30%) analogs (Fig. 3A and SI Appendix, Table S2).
Next, we installed a carboxylate group at the meta position on the
biphenyl B-ring (29β), intended to target the pocket formed by
N140 and R142, and found that 29β exhibited greater inhibition
(99%) compared with 28β when tested at 100 μM. This pronounced difference in activity was further highlighted when these
compounds were tested for inhibition at 10 μM and 1 μM (Fig. 3
B and C and SI Appendix, Table S2). Importantly, 30β (87%), the
methyl ester of 29β, tested at 100 μM resulted in a reduction in
binding, suggesting that the negative charge of the carboxylic acid
likely mediates a critical electrostatic interaction with R142 of
FmlHLD. Lastly, we synthesized the GalNAc version of 29β to
increase its binding affinity and found that 29β-NAc (93%) had
significant improvement in activity over 29β (75%) when tested at
10 μM. Final evaluation of the highest performing galactosides in
the ELISA-based competition assay at concentrations of 10 μM
and 1 μM allowed for a clearer ranking of compounds, where 29βNAc clearly stood out as the most potent (Fig. 3 B and C and SI
Appendix, Table S2).
Determination of FmlH–Galactoside Binding Affinities. Bio-layer interferometry (BLI) was pursued to quantitate the binding affinity
of the most promising FmlH antagonists. First, biotinylated serinelinked TF (Ser-TF) immobilized on streptavidin pins was incubated with varied titrations of FmlHLD in solution, and steady-state
analysis of binding responses revealed a dissociation constant (Kd)
E2824 | www.pnas.org/cgi/doi/10.1073/pnas.1720140115

of 15.0 ± 0.8 μM (Fig. 3D). Next, immobilized Ser-TF was incubated in solutions comprising a fixed concentration of FmlHLD
but varying concentrations of galactosides to determine their inhibitory or dissociation constant (Ki or Kd) values (Fig. 3E). The
BLI-based affinity determinations correlated well with the relative
binding strengths measured in the ELISA-based competition assay
(Fig. 3 A–C and SI Appendix, Table S2). The two lead compounds,
29β-NAc and 29β, bound tightly to FmlHLD, with respective Ki
values of ∼90 nM and 2.1 μM, which represent a ∼7,800-fold and
∼330-fold enhancement in binding affinity relative to Gal. Another
promising compound, 4β-NAc, bound FmlHLD with a Ki value of
2.3 μM. In summary, a combinatorial approach based on virtual
/screening and structure-guided ligand design led to the discovery of
small–molecular weight monomeric glycosides derived from Gal and
GalNAc that function as effective antagonists of FmlH. Optimization of early hits to high-affinity o-biphenyl Gal and GalNAc antagonists was realized via ortho substitution on phenyl aglycones to
facilitate interactions that significantly enhanced binding to FmlH.
Structural Basis of Galactoside Inhibition of FmlH. To elucidate the
molecular basis for galactoside inhibition of FmlH, cocrystal
structures of FmlHLD bound to 4β, 5β, 20β, and 29β-NAc were
determined (Fig. 4 A and B). These galactosides share a common
aglycone motif consisting of a phenyl ring with an ortho-substituted
functional group. As predicted from computational studies, the
sugar portion of all these galactosides resides within the cleft of the
binding pocket. The phenyl groups directly attached to the sugar
portion of all four compounds lie along the same 3D plane. In this
nearly identical conformation, the phenyl ring is oriented perpendicularly to the side chain of residue Y46, revealing edge-to-face
π-stacking, which likely contributes to the affinity enhancement observed for all β-galactosides. For 4β, 5β, and 20β, the ortho substituents point toward R142 but are too distant (>7 Å) for direct
interaction and, instead, form H-bonds with water molecules that,
in turn, interact with residues K132 and R142 (Fig. 4A). Thus, we
deduced that the marked affinity enhancement observed for 4β,
5β, and 20β is due to a combination of (i) indirect interactions
between the ortho substituent and residues K132 and R142 formed
by an intricate network of water-mediated H-bonds and (ii) edgeto-face π-stacking between the phenyl ring and residue Y46.
In contrast to simple phenyl galactosides, the biphenyl scaffold
of 29β-NAc presents the carboxylic acid to engage in a direct
Kalas et al.

charge–charge interaction with the guanidinium side chain of
R142 (Fig. 4B). The lower potency of the methyl ester derivative 30β is further evidence that the charge–charge interaction likely drives the observed affinity enhancement (Fig.
4C). The improved affinity of 29β-NAc relative to 29β is also
due to additional interactions mediated by the N-acetyl group
in H-bonding to a water molecule captured by the biphenyl
aglycone and the side chain of residue K132 (Fig. 4 B and C).
Altogether, analysis of all X-ray crystal structures of ligandbound FmlH offers two general mechanisms for the significant
enhancement in binding affinity of galactosides relative to
Gal: edge-to-face π-stacking with Y46 and polar or electrostatic charge–charge interactions with K132 and R142.
FmlH Antagonist Effectively Treats Murine UTI in Vivo and Prevents
Binding to Human Kidney Tissue. We previously reported that
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Fig. 5. Evaluation of galactosides for treatment of UTI and relevance in
humans. (A and B) Bacterial titers in bladders (A) or kidneys (B) from C3H/
HeN mice experiencing chronic cystitis transurethrally inoculated with 10%
DMSO (three replicates, n = 13), or 50 mg/kg of 4Z269 (three replicates, n =
13), of 29β-NAc (three replicates, n = 14), or of both 4Z269 and 29β-NAc (two
replicates, n = 9). Bars indicate median values. *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001; ns, not significant; two-tailed Mann–Whitney U test.
(C) Immunofluorescence analysis of FmlHLD WT, FmlHLD K132Q, or FmlHLD
WT in the presence of 29β-NAc binding to human bladder or human kidney
tissue. Green corresponds to FmlH, red corresponds to Wheat Germ Agglutinin, and blue corresponds to DAPI. Each image is representative of nine
total images (three imaged areas of three tissue slices). (Scale bars: 100 μm.)

Discussion
UPEC is the causative agent of most UTIs, a common and very
costly disease in women, children, and the elderly that is becoming
increasingly resistant to antibiotic treatment. By leveraging our
expertise in UPEC pathogenesis and structure-based drug design, we developed small-molecule Gal-based FmlH antagonists
that show in vivo efficacy in the treatment of chronic UTI in
mouse models. Virtual screening combined with rational design
led to the identification of several naturally occurring cranberry
and synthetic galactosides, the most potent of which binds FmlH
with nanomolar affinity. X-ray crystallography revealed that potent
galactosides achieve significant enhancements in binding affinity
through interactions on opposite sides of the wide Gal binding
pocket of FmlH. Appropriately substituted aryl groups, like those
found in 4β/4β-NAc, 5β, and 20β, are seen to mediate edge-to-face
π-stacking interactions with Y46 of FmlHLD. Further, the optimized
biphenyl aglycone of compound 29β-NAc contains an ideally positioned carboxyl group to mediate electrostatic interactions with
R142 in addition to π-stacking interactions with Y46. Evaluation
of the lead candidate 29β-NAc in a mouse model of chronic UTI
demonstrated significant reductions of bacterial burdens in the
mouse kidney and bladder. Combination dosing with mannoside
and galactoside resulted in near complete clearance of bacteria
from the kidney and significant elimination of bacteria from the
bladder. Furthermore, FmlH was shown to bind specifically to
PNAS | vol. 115 | no. 12 | E2825
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FmlH binds to naïve kidney and inflamed bladder tissue and
plays a critical role in chronic UTI, as abrogation of its function
through genetic deletion or vaccination results in significant attenuation in the ability of UPEC to cause chronic UTI (34).
Thus, we hypothesized that galactosides that inhibit the function
of FmlH would have efficacy in the treatment and/or prevention
of UTI. To assess therapeutic potential, the lead compound 29βNAc was evaluated for its ability to reduce bacterial burdens in
the urinary tracts of C3H/HeN mice during chronic UTI. We
previously defined chronic cystitis in C3H/HeN mice as urine
titers of >104 CFU/mL lasting at least 2 to 4 wk, as well as bladder
inflammation and edema at euthanasia (39). Further, C3H/HeN
mice are genetically predisposed to vesicoureteral reflux (retrograde flow of urine from the bladder to the kidneys), which can
lead to bacterial colonization of the kidneys, renal abscess formation, scarring, and atrophy (40). Accordingly, we observed high
levels of kidney colonization by CFT073 in control (vehicletreated) animals. When delivered intravesically, 29β-NAc significantly reduced bacterial burdens in both the bladder and the
kidneys of these mice (Fig. 5 A and B). For comparison, mannoside 4Z269, which inhibits the type 1 pilus adhesin FimH, also
significantly reduces titers of CFT073 from the bladders and
kidneys of infected mice relative to vehicle control (Fig. 5 A and
B). When administered together, 29β-NAc and 4Z269 eradicated
bacteria from the kidney in nearly all mice while also reducing
bacterial titers in the bladder, suggesting that FimH mannosides
and FmlH galactosides may function synergistically to target distinct
bacterial adhesins or communities within the kidney habitat (Fig.
5 A and B).
To show relevance to human UTI, we assessed FmlH and
FmlH-targeting galactosides through immunofluorescence analysis of FmlHLD binding to human kidney and bladder biopsied
tissue determined to be nonmalignant. While FmlHLD does not
appear to bind to healthy human bladder tissue, FmlHLD does
bind to healthy human kidney tissue, particularly in regions resembling the collecting ducts and distal tubules of the kidney
(Fig. 5C and SI Appendix, Figs. S4 and S5). As a negative control,
the binding null mutant FmlHLD K132Q, which lacks the ability
to bind ds-BSM in vitro (SI Appendix, Fig. S6), was incapable of
binding kidney tissue, suggesting that FmlHLD specifically recognizes receptors naturally present in human kidney tissue (Fig. 5C).
These observations are consistent with the previously reported
binding phenotypes in mice, in which FmlH can bind naïve mouse
kidney tissue, but not naïve mouse bladder tissue, and can bind to
receptors in inflamed bladder tissue (34). Moreover, incubation of
29β-NAc with FmlHLD prevented binding to human kidney tissue,
suggesting that these results may translate to humans. Importantly,
these collective data provide substantial evidence that aryl glycoside–
based FmlH antagonists derived from β-Gal or β-GalNAc can
serve as an effective therapy for persistent UTIs, including pyelonephritis, for which there is an enormous unmet medical need.

human kidney tissue, which could be inhibited by 29β-NAc.
Additionally, FmlH has been shown to be up-regulated in urine
samples directly isolated from human patients with UTI compared
with expression during in vitro growth in media or normal urine
(41), suggesting an important role for FmlH in human UTI. Thus,
FmlH-targeting galactosides represent a rational antivirulence
modality for the effective treatment of UPEC-mediated UTI.
Our rational strategy to discover receptor-mimicking galactosides targeting FmlH was similar to the strategy we followed for
the development of FimH mannosides. However, the design of
the galactoside and N-acetylgalactosaminoside antagonists of
FmlH was met with distinct challenges. The most striking difference between FmlH and FimH is the binding affinity for their
respective ligands: FimH binds soluble Man with a moderate
binding affinity of ∼5 to 10 μM, and FmlH binds soluble Gal with
a weak binding affinity of ∼700 μM (34, 42, 43). The weak binding
affinity of FmlH, which is quite common for most carbohydrate–
lectin interactions, rendered the development of high-affinity galactosides much more challenging. This disparity in affinity is a
direct consequence of the substantial variance in the shape of the
binding pocket. FimH binds Man with high affinity because of the
deep, narrow pocket formed by loops 1, 2, and 3, in which loops
2 and 3 mediate specific polar interactions directly to Man and a
water molecule and loop 1 serves as an affinity clamp to stymie
dissociation of Man (35). In contrast, loop 1 in FmlH is more
distant from loops 2 and 3 than it is in FimH and does not contribute to binding, which results in a widened, solvent-exposed
pocket for weak Gal binding (Fig. 1D). In addition, the differences in binding pocket architecture dictate the sterically allowed
linkage types. FimH has space at the tip of the LD between its
parallel tyrosine gate (residues Y48 and Y137) to accept α-linked
moieties, of which biaryl groups confer drastic enhancements in affinity through strong parallel face-to-face π-stacking interactions. In
contrast, FmlH is capped at the very tip of the pocket with Y46,
which biases specificity toward β-linked moieties, of which biaryl
groups confer moderate enhancements in affinity through significant edge-to-face π-stacking interactions. Having accounted for
these variations, our structure-guided medicinal chemistry approach,
coupled with our in vivo work, has clearly demonstrated the future
translational impact of galactosides as treatments for UTI.
It is noteworthy that our collective search for high-affinity
antagonists of FmlH and FimH has led to discovery of biphenyl
moieties as the preferred aglycone groups for high-affinity galactosides and mannosides, respectively. Pocket geometry dictates the
type of biphenyl scaffold that is optimal. Thus, the best FimHtargeting mannosides contain para biphenyls in the alpha stereochemistry, while the best FmlH-targeting galactosides contain ortho
biphenyls in the beta orientation. However, in both cases, Hbonding donors or acceptors on the B-ring result in significant
enhancement in binding affinity through specific interactions
outside the sugar binding pocket. Intriguingly, the inhibitory
potency conferred by the meta carboxyl on the B-ring of 29β-NAc
is also appreciated in the significant inhibitory role of the metasubstituted group on the B-ring in cranberry compounds 24β and
26β, which suggests a common pharmacophore between our
optimal synthetic compound and natural-product compounds in
targeting FmlH. This study provides evidence that specific glycosidic compounds in cranberry can specifically bind and inhibit
a bacterial adhesin. Furthermore, our work exposes a trend indicating that π-stacking of aromatic aglycones with binding pocket
residues in the adhesin is essential in mimicking glycoprotein receptors and for developing tight-binding ligands in each lectin.
Mimicking carbohydrates with small molecules is a long-soughtafter goal in medicinal chemistry and chemical biology (44–46),
and we believe that these results add significantly to this understanding and goal. This information can now be utilized not only in
the future optimization of lead compound 29β-NAc as a treatment
for UTIs, but also in the rational design of numerous other lectin
E2826 | www.pnas.org/cgi/doi/10.1073/pnas.1720140115

antagonists for the development of small-molecule glycoside-based
drugs aimed at treating infections mediated by E. coli or other microbes (44).
The rapid increase and spread of antibiotic resistance, including multidrug-resistant forms of bacteria, has rendered many
antibacterial therapies ineffective and threatens to undermine
the biomedical strides made to promote human health and
longevity (9). Selection pressures imposed by antibiotics on
bacterial pathogens have promoted their proliferation, especially
through overuse of antibiotics within the farming industry and
inappropriate use or misuse among patients (47–50). Recent
reports indicate that patients are now succumbing to bacterial
strains which possess broad-spectrum resistance to all last-resort
antibiotics, which many fear signals that antibiotic resistance will
pave the way for the “next pandemic” (15). Antivirulence strategies that aim to reduce the pathogenicity of bacterial pathogens
promise to provide the same therapeutic efficacy as antibiotics
without introducing selective pressures that would promote widespread dissemination of resistance (16). Multiple antivirulence efforts will be required to combat the multiple mechanisms by which
diverse bacterial pathogens colonize the host, which can include, for
example, the targeting of CUP pilus adhesins or the biogenesis
machinery responsible for the assembly of CUP pili (51). As
highlighted in this work, UPEC employs an armament of diverse
CUP pili to colonize and persist within changing local environments encountered during UTI pathogenesis, which suggests that
targeting more than one CUP adhesin may indeed be a more effective strategy for combating UTIs. Herein, we have highlighted
the overwhelming value of applying a deep mechanistic understanding of structure-function-virulence relationships of bacterial
adhesins to the rational design of high-affinity carbohydrate glycomimetics for the treatment of UTI. This demonstration serves as
a general model for the rational approach necessary to target virulence factors and disrupt their role in bacterial infections.
Materials and Methods
Ethics Statement. All animal experiments were conducted according to the
National Institutes of Health (NIH) guidelines for housing and care of laboratory animals and performed in accordance with institutional regulations
after pertinent review and approval by the Institutional Animal Care and Use
Committee at Washington University School of Medicine (protocol 20150226).
Deidentified human tissue was obtained from the Tissue Procurement Core at
Washington University School of Medicine.
Protein Expression and Purification. FmlH residues 1 to 160 from UPEC strain
UTI89 with a C-terminal six-histidine tag (i.e., FmlHLD) were cloned into the
IPTG-inducible plasmid pTrc99A. This construct was then transformed into
and expressed in E. coli strain C600. Periplasms were isolated as previously
described and dialyzed four times against PBS plus 250 mM NaCl (34). FmlHLD
was purified from this periplasmic fraction by cobalt affinity chromatography through elution with 150 mM imidazole. FmlHLD was buffer exchanged
into 10 mM Hepes [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] (pH
7.5) and 50 mM NaCl, concentrated to 6 mg/mL, and stored stably at 4 °C for
use in biochemical and biophysical assays.
In Silico Docking and Virtual Screening. Structure-based virtual screening
through in silico docking was performed with AutoDock Vina (52). Existing
Gal-based derivatives were identified through the ZINC12 database (53).
Their 3D structures were extracted from the downloaded mol2 file as pdb
coordinates and converted to pdbqt format using Open Babel (54). The
crystal structure of apo FmlH was converted to its topology file using
AutoDock Tools. The grid box was centered at the Gal binding pocket of
FmlH, and its dimensions (26 × 26 × 26 Å3) were chosen to accommodate
bulky compounds and multiple potential binding modes at or near the
binding pocket. The exhaustiveness of the search was set to a value of 15.
The top binding modes and scores within this grid space were generated by
AutoDock Vina. Custom in-house scripts in Bash and MATLAB were used to
link these binding scores with compound properties such as molecular
weight. Top binding modes were visualized in PyMOL.
Virtual screening of this library, which comprised galactosides ranging
from 150 to 900 Da in molecular mass, yielded a mean docking score of
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Synthesis of Galactosides and N-acetyl Aminogalactosides. Galactosides and
N-acetyl aminogalactosides were synthesized by standard glycosylation
chemistry, including boron trifluoride-mediated glycosidation and the Koenigs–
Knorr reaction, respectively (SI Appendix, Fig. S2). In method A, boron trifloridepromoted glycosylation of phenols with Gal pentaacetate yielded corresponding
acetylated aryl galactosides, which were treated with sodium methoxide in
methanol to provide the corresponding aryl galactosides (1β to 3β, 5β to 9β, 18β
to 19β, and 28β to 32β; 2α to 3α, 18α to 19α, and 28α to 32α). In method B, final
GalNAc and Gal analogs (20β-NAc, 21β, 28β-NAc, and 29β-NAc) were synthesized
from galactosyl halide and aryl alcohols via a Koenigs–Knorr-type reaction, which
yielded aryl galactosides that were then deacetylated by treatment with
methylamine in ethanol.
ELISA. Immulon 4HBX 96-well plates were coated overnight with 1 μg of
bovine submaxillary mucin (Sigma). Coated wells were then treated with
100 μL of Arthrobacter ureafaciens sialidase (10 mU/mL) diluted in PBS for
1 h at 37 °C. Thereafter, wells were incubated with 200 μL of blocking buffer
(PBS plus 1% BSA) for 2 h at 23 °C, followed by incubation with 100 μL of
biotinylated FmlHLD diluted in blocking buffer to 20 μg/mL in the presence or
absence of galactoside compounds for 1 h at 23 °C. After washing three
times with PBS plus 0.05% TWEEN-20, 100 μL of streptavidin-HRP conjugate
(BD Biosciences; 1:2,000 dilution in blocking buffer) was added to each well
for 1 h at 23 °C. After a final round of washing, plates were developed with
100 μL of tetramethylbenzidine (BD Biosciences) substrate and quenched
within 1 to 2 min with 50 μL of 1 M H2SO4, and absorbance was measured at
450 nm. This assay was used to determine percent inhibition values and
inhibitory constant (IC50) values where indicated.
BLI. Streptavidin pins were first dipped in a baseline in PBS (pH 7.4) for 120 s,
followed by loading of 5 to 10 μg/mL biotinylated Ser-TF (Toronto Research
Chemicals) in PBS for 300 s, quenching by 10 μg/mL biocytin in PBS for 240 s,
and another baseline step in PBS for 120 s. Thereafter, pins were dipped in
PBS for 120 s and transferred to protein samples (varying concentration of
FmlHLD or fixed concentration of FmlHLD with varying concentration of galactoside compounds) for association for 300 to 600 s. Equilibrium binding
response values were used to determine the affinity of interaction between
FmlHLD and immobilized Ser-TF under a 1:1 binding model or between FmlHLD
and galactosides in solution under a competitive one-site binding model.
Protein Crystallization and Structure Determination. Crystals of apo FmlHLD in
10 mM Hepes (pH 7.5) and 50 mM NaCl were grown by mixing 2 μL of
protein (6 mg/mL) with 2 μL of mother liquor [0.2 M ammonium sulfate,
0.1 M NaCl, 0.1 M Mes [2-(N-morpholino)ethanesulfonic acid] (pH 5.6), and
28% PEG 3350] and equilibrated against 1 mL of mother liquor in the reservoir. Cocrystals of FmlHLD bound to TF or galactosides 4β (in space group P
2 21 21), 5β, and 20β were grown by mixing 2 μL of protein (6 mg/mL) in the
presence of 5 mM compound with 2 μL of mother liquor [0.2 M ammonium
sulfate, 0.1 M NaCl, 0.1 M Mes (pH 5.6), and 32% PEG 3350] and equilibrated
against 1 mL of mother liquor in the reservoir. These crystals were transferred into cryoprotectant [0.2 M ammonium sulfate, 0.1 M NaCl, 0.1 M Mes
(pH 5.6), 35% PEG 4000, and 10% glycerol] and then flash frozen in liquid
nitrogen. Cocrystals of FmlHLD bound to the galactoside 29β-NAc were
grown by mixing 2 μL of protein complex (10 mg/mL FmlHLD with a 1.2:1
molar ratio of 29β-NAc to FmlHLD) with 2 μL of mother liquor (0.7 M LiSO4
1. Foxman B (2003) Epidemiology of urinary tract infections: Incidence, morbidity, and
economic costs. Dis Mon 49:53–70.
2. Griebling TL (2005) Urologic diseases in America project: Trends in resource use for
urinary tract infections in women. J Urol 173:1281–1287.
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and 2% PEG8000) and equilibrated against 1 mL of mother liquor in the
reservoir. These crystals were transferred into cryoprotectant (1 M LiSO4,
10% PEG8000, and 25% glycerol). Diffraction data for TF, 4β (in space group C
1 2 1), and 29β-NAc structures were collected at 100 K at an in-house facility
equipped with a rotating anode Rigaku MicroMax 007 generator, a Rayonix
Marmux X-ray source, and a Mar345 image plate detector. Diffraction data for
apo, 4β, 5β, and 20β structures were collected at 100 K at the ALS Beamline
4.2.2. Data were indexed and integrated in iMosflm (55), XDS (56), or
HKL2000 and scaled by Scala (57). The phase problem was solved by molecular
replacement using Phaser-MR in PHENIX (58) with FimHLD from PDB ID 3MCY.
Several rounds of refinements were performed in PHENIX to improve the
final models.
Mouse Infections. Seven- to 8-wk-old female C3H/HeN mice were obtained
from Envigo. Mice were anesthetized and inoculated via transurethral catheterization with 50 μL of CFT073 bacterial suspension (∼1 × 108 to 2 × 108 CFU in
total) in PBS. Mice experiencing high titers of bacteriuria (>104 CFU/mL) and
edematous and inflamed bladders when killed after 2 wk, or chronic cystitis
(39), were then transurethrally inoculated either with 50 mg/kg compound or
vehicle control (10% DMSO). Mice were killed 6 h posttreatment, and bacteria
colonizing the bladder or kidney were plated for quantification.
Immunofluorescence. Frozen, deidentified human bladder and kidney sections
were obtained from the Tissue Procurement Core and stored stably at −80 °C.
These tissue section slides were removed from the freezer and allowed to
thaw at room temperature for 10 to 20 min. After applying a hydrophobic
barrier pen around the tissue, slides were rehydrated in 200 μL buffer (5%
BSA and 0.2% Triton X-100 in PBS) for 10 min. Buffer was gently aspirated
and slides were blocked for 1 h at room temperature with 200 μL of buffer.
Thereafter, buffer was gently aspirated and slides were incubated with
200 μL of sample overnight at 4 °C. Samples diluted in buffer included 50 μg/mL
FmlHLD wild-type (WT), 50 μg/mL FmlHLD K132Q, and 50 μg/mL FmlHLD WT incubated with 100 μM 29β-NAc. Samples were gently aspirated and slides were
washed three times in buffer for 5 min each. Next, slides were incubated with our
mouse anti-FmlH polyclonal antibody (1:500 dilution in buffer) for 1 h at room
temperature. Slides were washed again three times in buffer and then incubated
in the dark with donkey anti-mouse IgG Alexa Fluor 594 and Wheat Germ
Agglutinin Alexa Fluor 633 (each 1:500 dilution in buffer) for 1 h at room
temperature. Slides were washed once with buffer and then incubated in the
dark with DAPI (1:1,000 dilution in buffer) for 5 min at room temperature. After
washing twice with buffer, coverslips were mounted using 80 μL of mounting
media. Slides were loaded onto a Zeiss LSM 880 Confocal Laser Scanning Microscope (Carl Zeiss, Inc.) equipped with a diode 405 to 430 laser, a HeNe 543
laser, and a HeNe 633 laser. Images were acquired with a 20×, 0.8 numerical
aperture Zeiss Plan Apochromat objective using ZEN 2 imaging software.
Statistics. Mouse data are compiled from two (4Z269 plus 29β-NAc) or three
(all other treatments) independent experiments, with four or five mice per
group per experiment. These data were analyzed using the uncorrected
two-tailed Mann–Whitney U test in GraphPad Prisim v.5. ELISA data are
reported as box-and-whisker plots indicating the mean, 2.5th, 25th, 75th,
and 97.5th percentiles of at least two independent experiments, with three
technical replicates per experiment.
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